Stop wasting hours on dense SEC filings. Get AI-powered summaries of any SEC Filings in seconds. Understand key insights and risks, fast.
Currently we only process Form 8-K, 6-K, 3, 4, 144, Schedule 13D and Schedule 13G. We will support more forms in the future.
Filter by Form Type:
Industry:Biotechnologyβ
2026-07-17IKT3Ownership Filing for RA Capital Management, L.P. - Inhibikase Therapeutics, Inc.HIGH
This filing indicates that RA Capital Management, L.P., along with its associated fund and individuals Dr. Peter Kolchinsky and Mr. Rajeev Shah, collectively hold a significant ownership stake in Inhibikase Therapeutics, Inc. (IKT). RA Capital Management, L.P. functions as the investment manager for the RA Capital Heal...
Small CapBiotechnology
2026-07-17Inhibikase Therapeutics, Inc.3Ownership Filing for RA Capital Management, L.P. - Inhibikase Therapeutics, Inc.DuplicateHIGH
This filing indicates that RA Capital Management, L.P., along with its associated fund and individuals Dr. Peter Kolchinsky and Mr. Rajeev Shah, collectively hold a significant ownership stake in Inhibikase Therapeutics, Inc. (IKT). RA Capital Management, L.P. functions as the investment manager for the RA Capital Heal...
Small CapBiotechnology
2026-07-17Inhibikase Therapeutics, Inc.3Ownership Filing for RA Capital Management, L.P. - Inhibikase Therapeutics, Inc.DuplicateHIGH
This filing indicates that RA Capital Management, L.P., along with its associated fund and individuals Dr. Peter Kolchinsky and Mr. Rajeev Shah, collectively hold a significant ownership stake in Inhibikase Therapeutics, Inc. (IKT). RA Capital Management, L.P. functions as the investment manager for the RA Capital Heal...
Small CapBiotechnology
2026-07-17BHVN3Biohaven Ltd. Insider Filing SummaryMEDIUM
This filing details the ownership and derivative holdings of Warren Volles, Chief Legal Officer of Biohaven Ltd. As of July 9, 2026, Volles directly owns 248,212 common shares. The filing also discloses various stock options and restricted share units granted to Volles, with exercise prices ranging from $7 to $41.93 an...
Mid CapBiotechnology